AREV Life Sciences Global Corp. announced its initial research engagement with TransBIOTech. TransBIOTech is also supported by the Canadian Foundation for Innovation and by the Government of Quebec.

TransBIOTech is a member of Tech-Access Canada, a national organization of Technology Access Centres as well as a member of Synchronex, a network of Quebec province College Centres for the Transfer of Technologies. TransBIOTech laboratory facility utilizes more than $16 million in equipment and offers an animal facility accredited by the Council on Animal Care of Canada. TransBIOTech is a multi-sectional research facility with expertise in the life sciences sector, specializing in analytical chemistry, biochemistry, cell & molecular biology, and microbiology for pharmaceutical sciences.

With capabilities in various project stages including in vitro, in cellulo, and in vivo functional assays (biomarkers, cytotoxicity, anti-inflammatory properties, and antimicrobial activity as well as analysis of pharmacological properties of molecules (permeability, metabolic stability, ADME and toxicology). The collaboration between AREV and TransBIOTech will facilitate further development of proprietary immune modulatory therapeutics derived from phytomedicinal research that addresses pandemic infectious disease affecting host responses to elevated cytokine expression. AREV, in conjunction with TransBIOTech, is also designing preclinical characterization studies to identify suspected therapeutic characteristics of other botanically-derived compounds identified in peer-reviewed literature including phytocannabinoids and Cucumaria frondosa leading to small molecule candidates for human studies.

The initial studies being designed by TransBIOTech, in collaboration with members of the AREV Scientific Advisory Board (SAB), will provide correspondence of the subsequent published results of these studies to public research programs including The National Institute of Health's Accelerating Covid-19 Therapeutic Interventions and Vaccines, AIDS Clinical Trial Groups of the National Institute of Allergy and Infectious Diseases and President Biden's White House Cancer Cabinet.